20/20 Biolabs, Inc. (AIDX)
NCM · Healthcare · Medical Devices
$0.56
+3.70%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$7.2M
Shares Outstanding
12.8M
P/S (TTM)
3.5x
Exchange
NCM
Currency
USD
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 418K | 538K | 353K | 731K |
| Gross Profit | 145K | 130K | 63K | 305K |
| Operating Income | (800K) | (913K) | (1.4M) | (1.2M) |
| Net Income | (826K) | (1.3M) | (2.2M) | (1.5M) |
| Diluted EPS | N/A | N/A | $-0.28 | $-0.26 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 1.4M | 1.8M | 2.0M |
| Gross Profit | 109K | 360K | 605K |
| Operating Income | (6.4M) | (5.7M) | (3.3M) |
| Net Income | (6.4M) | (5.6M) | (3.7M) |
| Diluted EPS | $-0.62 | $-0.54 | $-0.36 |